The report provides a detailed analysis essential for establishing a Dantrolene production plant. It encompasses all critical aspects necessary for Dantrolene production, including the cost of Dantrolene production, Dantrolene plant cost, Dantrolene production costs, and the overall Dantrolene production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Dantrolene production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Dantrolene is an FDA-approved medication used in both adults and children for the management of malignant hyperthermia, an extremely uncommon but potentially fatal condition brought on by general anesthesia. Additionally, Dantrolene has been licensed by the FDA for use in other conditions such as multiple sclerosis, cerebral palsy, spinal cord injury, stroke, and disorders involving muscle spasticity. Dantrolene is also used to treat overdoses of 2,4-dinitrophenol, which is a “fat burner” drug that is illegal and inhibits ATP production, resulting in hyperthermia.
The market for Dantrolene is driven by its usage as a hydantoin derivative and skeletal muscle relaxant for the treatment of malignant hyperthermia, which significantly promotes its demand in the pharmaceutical and medical industries. The widespread occurrence of malignant hyperthermia is significantly increasing the demand for Dantrolene. The aging population is more susceptible to muscle stiffness and frequent muscle spasms, which accelerates the demand for muscle relaxants like Dantrolene.
The drug’s utility extends to off-label uses, such as multiple sclerosis, cerebral palsy, spinal cord injury, and muscle spasticity, which further promotes its demand in the pharmaceutical industry and amplifies its market presence. Overall, industrial Dantrolene procurement is influenced by its usage in the pharmaceutical and medical industries, rising cases of malignant hyperthermia, off-label uses, increasing healthcare awareness, technological advancements, and regulatory approvals.
Raw Material for Dantrolene Production
According to the Dantrolene production plant project report, the key raw material used in the production of Dantrolene includes 4-nitrophenyldiazonium chloride.
Production Process of Dantrolene
The extensive Dantrolene production cost report consists of the following major industrial production process:
- Production from 4-nitrophenyldiazonium chloride: The production process of Dantrolene starts with the reaction of the starting compound with furfurol to form 5-(4-nitrophenyl)-2-furancarboxaldehyde. The compound further reacts with 1-aminohydantoin, to produce the corresponding hydrazone, Dantrolene.
Dantrolene, commercially known as Dantrium, Revonto, or Ryanodex, is an odorless and tasteless substance having the molecular formula C14H10N4O5 and a molecular weight of 314.25 g/mol. It has a melting point in the range of 279-280 °C. It has a low (146 mg/L) water solubility. It has an estimated water solubility of 0.0805 mg/mL. It is easily soluble in alkaline solution. It has a log P value of 1.70. The value of its dissociation constant, pKa, is 8.23. It remains stable in light, air, and heat but hydrolyzes in water. It decomposes between the range of 225 & 230 °C. It is rapidly observed after oral administration. Although Dantrolene is a derivative of hydantoin chemically, it lacks the antiepileptic properties of phenytoin and other hydantoin derivatives. It is a skeletal muscle relaxant used to treat malignant hyperthermia.